Search
for
Sort by
Research 151–180 of 1000+
- Aberrant inflammasome activation as a driving force of human autoimmune skin disease
- Gut Microbiota and Autoimmune Alopecia Areata: Current Insights from the Literature
- Modern Management Approaches for Alopecia Areata
- Alopecia Areata: Current Review
- Skin aging: mechanisms, evaluation, and rejuvenation
- Differential impact of environmental factors on systemic and localized autoimmunity
- Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
- Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Novel therapies for alopecia areata: The era of rational drug development
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- New treatment modalities of alopecia areata
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Tangled Causes, Targeted Solutions: A Comprehensive Review of Alopecia.
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Immune therapies for alopecia areata: evidence and new perspectives
- AIRE Deficiency Leads to the Development of Alopecia Areata‒Like Lesions in Mice
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Alopecia areata: What’s new in the epidemiology, comorbidities, and pathogenesis?
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- New Modalities in the Treatment of Refractory Alopecia Areata
- Dietary Habits in Japanese Patients with Alopecia Areata
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Janus kinase inhibitors for alopecia areata: A narrative review
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Alopecia areata susceptibility variant in MHC region impacts expressions of genes contributing to hair keratinization and is involved in hair loss